KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Minority Interest (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Minority Interest for 16 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Minority Interest fell 42.86% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2025, down 42.86%, and an annual FY2025 reading of $4.0 million, down 42.86% over the prior year.
  • Minority Interest was $4.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $7.0 million in the prior quarter.
  • Across five years, Minority Interest topped out at $987.0 million in Q2 2021 and bottomed at $4.0 million in Q4 2025.
  • Average Minority Interest over 5 years is $621.9 million, with a median of $751.0 million recorded in 2022.
  • The sharpest move saw Minority Interest fell 1.5% in 2021, then crashed 98.87% in 2024.
  • Year by year, Minority Interest stood at $966.0 million in 2021, then decreased by 17.81% to $794.0 million in 2022, then decreased by 21.91% to $620.0 million in 2023, then plummeted by 98.87% to $7.0 million in 2024, then crashed by 42.86% to $4.0 million in 2025.
  • Business Quant data shows Minority Interest for TEVA at $4.0 million in Q4 2025, $7.0 million in Q4 2024, and $319.0 million in Q3 2024.